Here are relevant reports on : antibody-drug-conjugates-market
-
Sterile Filtration Market by Product (Cartridge, Capsule Filter), Application (API, Vaccine, Antibody, Media, Formulation & Fill Finish), Membrane (PES, PVDF, PTFE), Pore Size, End User (Pharma & Biotech, F&B, CMO) - Global Forecast to 2028
The global sterile filtration market, valued at US$8.2 billion in 2022, stood at US$8.9 billion in 2023 and is projected to advance at a resilient CAGR of 11.4% from 2023 to 2028, culminating in a forecasted valuation of US$15.3 billion by the end of the period. The growth of this market is majorly driven by demand for sterile filtration in pharmaceutical companies and the food and beverage industries.
- Published: April 2023
- Price: $ 4950
- TOC Available:
-
Western Blotting Market by Product, (Consumables (Antibody), Instrument (Electrophoresis, Blotting System, Imager (Fluorescent))), Application (Biomedical, Clinical Diagnostics), End User (Research Institute, Hospital, Biopharma) & Region - Global Forecast to 2026
The global western blotting market growth is primed to transition from $1.0 billion in 2021 to $1.4 billion by 2026, showcasing a strong CAGR of 6.7%. Technological advancements, increasing government funding in the field of biomedical research, growing demand for personalized medicine, and the rising prevalence of HIV are the key factors driving the market growth.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) - Global Forecast to 2021
The global antinuclear antibody test market size is projected to grow at a CAGR of 12.4%. This market is segmented based on products, diseases, techniques, end users, and regions. On the basis of products, the ANA testing market is segmented into assay kits & reagents, systems, and software & services. The assay kits & reagents segment is expected to account for the largest share of the global ANA testing market, primarily due to the growing number of reagent rental agreements and increasing prevalence of autoimmune diseases worldwide.
- Published: September 2016
- Price: $ 4950
- TOC Available:
-
Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti–Epileptic Drugs,Anti–Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
The global therapeutic drug monitoring market, valued at US$2.14 billion in 2023, stood at US$2.30 billion in 2024 and is projected to advance at a resilient CAGR of 8.4% from 2024 to 2029, culminating in a forecasted valuation of US$3.44 billion by the end of the period. This growth is brought on by a number of causes, such as the rise in chronic diseases like cancer, heart disease, epilepsy, and autoimmune conditions.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Drug Screening Market Size by Product (Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Urine, Breath, Hair), Drug (Alcohol, Cannabis, Opioids), End User (Workplace, Hospital, Law) - Global Forecast to 2029
The global drug screening market, valued at US$7.7 billion in 2023, stood at US$9.1 billion in 2024 and is projected to advance at a resilient CAGR of 16.6% from 2024 to 2029, culminating in a forecasted valuation of US$19.5 billion by the end of the period. The growth of the drug screening market is driven by the growing drug & alcohol consumption and the enforcement of stringent laws mandating drug & alcohol testing.
- Published: May 2024
- Price: $ 4950
- TOC Available:
-
Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030
The global biopharmaceutical contract manufacturing market, valued at US$20.51 billion in 2024, stood at US$22.40 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$34.15 billion by the end of the period. The growth is primarily driven by the rising demand for outsourcing services and an increasing need for biologics and biosimilars. However, challenges related to intellectual property rights are anticipated to pose barriers to market growth.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Glioblastoma Multiforme Drug Market by Therapy (Chemotherapy, Immunotherapy), Drug Class, End Use, Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast to 2027
The global glioblastoma multiforme drug market is projected to reach USD ~880 million by 2027 from USD 600 million in 2022, at a CAGR of 8% during the forecast period
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Life Science Analytics Market by Type (Descriptive, Prescriptive, Predictive), by Service (Analytics), Application (Drug Discovery, Trials, RWE, Access, Sales & Marketing, Drug Safety), End User (Pharma, Medical Device) & Region - Global Forecast to 2030
Global life science analytics market valued at $35.69B in 2024, reached $40.03B in 2025, and is projected to grow at a robust 11.4% CAGR, hitting $68.81B by 2030. Emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Chemoinformatics Market by Application (Chemical Analysis (Chemical Databases, Chemo Metrics, Molecular Modelling), Drug Discovery (High Throughput Screening, Lead Identification and Optimization, QSAR/QSPR), Drug Validation) - Global Forecast to 2023
Growth of the chemoinformatics market is primarily driven by innovations and advancements in the drug development process, advances in the computer technology, increased demand of personalized medicine. On the other hand, cost associated with the chemoinformatics software is one of the major factors restraining the growth of this market. Whereas emerging markets are expected to provide significant growth opportunities in this market.
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
